These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 16801350)

  • 1. Antipsychotics and cognitive decline in Alzheimer's disease: the LASER-Alzheimer's disease longitudinal study.
    Livingston G; Walker AE; Katona CL; Cooper C
    J Neurol Neurosurg Psychiatry; 2007 Jan; 78(1):25-9. PubMed ID: 16801350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine.
    Suh DC; Arcona S; Thomas SK; Powers C; Rabinowicz AL; Shin H; Mirski D
    Drugs Aging; 2004; 21(6):395-403. PubMed ID: 15084141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotics, cognitive decline and death in Alzheimer's disease: the London and South-East Region Alzheimer's Disease longitudinal study.
    Ames D
    J Neurol Neurosurg Psychiatry; 2007 Jan; 78(1):2. PubMed ID: 17172562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Impact of treatment with acetylcholinesterase inhibitors, valproic acid and antipsychotics on aggressive behaviour in Alzheimer's type dementia].
    Bidzan L; Grabowski J; Dutczak B; Bidzan M
    Psychiatr Pol; 2012; 46(3):361-72. PubMed ID: 23045890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of psychotropic medications in relation to neuropsychiatric symptoms, cognition and functional performance in Alzheimer's disease over a three-year period: Kuopio ALSOVA study.
    Törmälehto S; Martikainen J; Bell JS; Hallikainen I; Koivisto AM
    Int Psychogeriatr; 2017 Oct; 29(10):1723-1733. PubMed ID: 28625207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive effects of atypical antipsychotics in patients with Alzheimer's disease and comorbid psychiatric or behavioral problems: a retrospective study.
    Caballero J; Hitchcock M; Scharre D; Beversdorf D; Nahata MC
    Clin Ther; 2006 Oct; 28(10):1695-700. PubMed ID: 17157125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of commonly prescribed drugs in patients with Alzheimer's disease on the rate of deterioration.
    Ellul J; Archer N; Foy CM; Poppe M; Boothby H; Nicholas H; Brown RG; Lovestone S
    J Neurol Neurosurg Psychiatry; 2007 Mar; 78(3):233-9. PubMed ID: 17012333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cognitive decline in Alzheimer's disease. A follow three or more years of a sample of patients].
    Conde-Sala JL; Garre-Olmo J; Vilalta-Franch J; Llinàs-Reglà J; Turró-Garriga O; Lozano-Gallego M; Hernández-Ferràndiz M; Pericot-Nierga I; López-Pousa S
    Rev Neurol; 2013 Jun; 56(12):593-600. PubMed ID: 23744245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hallucinations, cognitive decline, and death in Alzheimer's disease.
    Wilson RS; Tang Y; Aggarwal NT; Gilley DW; McCann JJ; Bienias JL; Evans DA
    Neuroepidemiology; 2006; 26(2):68-75. PubMed ID: 16352909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of cerebral emboli with accelerated cognitive deterioration in Alzheimer's disease and vascular dementia.
    Purandare N; Burns A; Morris J; Perry EP; Wren J; McCollum C
    Am J Psychiatry; 2012 Mar; 169(3):300-8. PubMed ID: 22193532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease.
    Rosenberg PB; Mielke MM; Han D; Leoutsakos JS; Lyketsos CG; Rabins PV; Zandi PP; Breitner JC; Norton MC; Welsh-Bohmer KA; Zuckerman IH; Rattinger GB; Green RC; Corcoran C; Tschanz JT
    Int J Geriatr Psychiatry; 2012 Dec; 27(12):1248-57. PubMed ID: 22374884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
    Liu-Seifert H; Siemers E; Price K; Han B; Selzler KJ; Henley D; Sundell K; Aisen P; Cummings J; Raskin J; Mohs R;
    J Alzheimers Dis; 2015; 47(1):205-14. PubMed ID: 26402769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia.
    Kennedy J; Deberdt W; Siegal A; Micca J; Degenhardt E; Ahl J; Meyers A; Kaiser C; Baker RW
    Int J Geriatr Psychiatry; 2005 Nov; 20(11):1020-7. PubMed ID: 16250069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD).
    Ballard C; Thomas A; Gerry S; Yu LM; Aarsland D; Merritt C; Corbett A; Davison C; Sharma N; Khan Z; Creese B; Loughlin P; Bannister C; Burns A; Win SN; Walker Z;
    J Am Med Dir Assoc; 2015 Apr; 16(4):316-22. PubMed ID: 25523285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.
    Wattmo C; Minthon L; Wallin ÅK
    Alzheimers Res Ther; 2016 Feb; 8():7. PubMed ID: 26883213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
    Daiello LA
    Med Health R I; 2007 Jun; 90(6):191-4. PubMed ID: 17633594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
    Portelius E; Zetterberg H; Skillbäck T; Törnqvist U; Andreasson U; Trojanowski JQ; Weiner MW; Shaw LM; Mattsson N; Blennow K;
    Brain; 2015 Nov; 138(Pt 11):3373-85. PubMed ID: 26373605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration.
    Stern RG; Mohs RC; Davidson M; Schmeidler J; Silverman J; Kramer-Ginsberg E; Searcey T; Bierer L; Davis KL
    Am J Psychiatry; 1994 Mar; 151(3):390-6. PubMed ID: 8109647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychotropic Medication and Cognitive, Functional, and Neuropsychiatric Outcomes in Alzheimer's Disease (AD).
    Oh ES; Rosenberg PB; Rattinger GB; Stuart EA; Lyketsos CG; Leoutsakos JS
    J Am Geriatr Soc; 2021 Apr; 69(4):955-963. PubMed ID: 33382921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of ninjin'yoeito, a Kampo (traditional Japanese) medicine, on cognitive impairment and depression in patients with Alzheimer's disease: 2 years of observation.
    Kudoh C; Arita R; Honda M; Kishi T; Komatsu Y; Asou H; Mimura M
    Psychogeriatrics; 2016 Mar; 16(2):85-92. PubMed ID: 25918972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.